Bradway Robert A 4

What Happened
Robert A. Bradway, Amgen's Chairman, CEO and President, had 2,079 shares withheld to cover a tax liability related to equity awards. The shares were valued at $331.11 each, for a total of approximately $688,378. This disposition reflects tax withholding (transaction code F), not an open-market sale.

Key Details

• Transaction date: 2026-05-07; Form 4 filed: 2026-05-11 (filed within the standard two business-day window).
• Shares withheld/disposed: 2,079 shares at $331.11 per share; total value ≈ $688,378.
• Shares owned after transaction: Not reported in the provided filing excerpt.
• Footnote: 1,273 of the withheld shares were Dividend Equivalents (DEs) credited to unvested Restricted Stock Units and paid out in shares on a one-to-one basis per the vesting schedule (with cash for any fractional share).
• Transaction type: Tax withholding on equity awards (routine administrative action), not a purchase (code F).

Context
Withholding shares to cover taxes on vested awards is a common administrative step and is generally considered routine rather than a signal of the insider’s view on the stock. The filing indicates these were linked to RSU-related dividend equivalents; no open-market sale or 10b5‑1 plan was reported in the provided excerpt.